GlobeNewswire: Isracann Biosciences Inc. Contains the last 10 of 72 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T17:47:19ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/10/13/2533875/0/en/Isracann-Biosciences-Provides-Bi-Weekly-Default-Status-Report.html?f=22&fvtc=4&fvtv=43461Isracann Biosciences Provides Bi-Weekly Default Status Report2022-10-13T12:30:00Z<![CDATA[VANCOUVER, British Columbia, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) announces that further to its news release dated September 29, 2022 (the “Default Announcement”), the Company’s principal regulator, the British Columbia Securities Commission (the “BCSC”) granted a management cease trade order (the “MCTO”) on September 29, 2022, under National Policy 12-203 Management Cease Trade Orders (“NP 12-203”).]]>https://www.globenewswire.com/news-release/2022/09/29/2525683/0/en/Isracann-Biosciences-Announces-Delay-in-Filing-Annual-Financial-Statements.html?f=22&fvtc=4&fvtv=43461Isracann Biosciences Announces Delay in Filing Annual Financial Statements2022-09-29T22:25:40Z<![CDATA[VANCOUVER, British Columbia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) announces that the filing of its audited annual financial statements for the year ended May 31, 2022, including the related management discussion and analysis, and CEO and CFO certifications (collectively, the “Annual Financial Filings”) were not filed by the required filing deadline of September 28, 2022 (the “Filing Deadline”). The Annual Financial Filings are late due to unforeseen delays in the completion of the Company’s audit. The unforeseen delay is due to the fact that the Company acquired operations in Israel and in Canada during the fiscal period and the auditors are trying to consolidate the audit and have lack of time to complete procedures.]]>https://www.globenewswire.com/news-release/2022/09/28/2524376/0/en/Isracann-Bioscience-Facilitated-Genetics-Arrive-in-Israel.html?f=22&fvtc=4&fvtv=43461Isracann Bioscience Facilitated Genetics Arrive in Israel2022-09-28T13:00:00Z<![CDATA[Partner Facility Now Growing Canadian Cannabis Strains Partner Facility Now Growing Canadian Cannabis Strains]]>https://www.globenewswire.com/news-release/2022/09/14/2515977/0/en/Isracann-Bioscience-Facilitates-Cannabis-Genetics-Shipment-to-Israel.html?f=22&fvtc=4&fvtv=43461Isracann Bioscience Facilitates Cannabis Genetics Shipment to Israel2022-09-14T12:30:00Z<![CDATA[VANCOUVER, British Columbia, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”), a multi-faceted Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor, is pleased to announce it has facilitated its first shipment of cannabis strains to Israel.]]>https://www.globenewswire.com/news-release/2022/09/01/2508614/0/en/Praesidio-signs-distribution-agreement-with-Pure-Integrative-Pharmacy.html?f=22&fvtc=4&fvtv=43461Praesidio signs distribution agreement with Pure Integrative Pharmacy2022-09-01T13:00:00Z<![CDATA[VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted organization with a natural health medicine division (Praesidio Health) in Canada and holdings in Israel, is please to announce that it has signed a distribution agreement for Praesidio Health (Praesidio) products with Pure Integrative Pharmacy (PURE).]]>https://www.globenewswire.com/news-release/2022/08/23/2503039/0/en/Isracann-Adds-Super-Bowl-MVP-and-Mental-Health-Advocate-Mark-Rypien-to-Advisory-Board.html?f=22&fvtc=4&fvtv=43461Isracann Adds Super Bowl MVP and Mental Health Advocate Mark Rypien to Advisory Board2022-08-23T13:00:00Z<![CDATA[VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted organization with a natural health medicine division (Praesidio Health) in Canada and holdings in Israel, is please to announce the appointment of Super Bowl XXVI MVP and mental health advocate Mr. Mark Rypien to its advisory board.]]>https://www.globenewswire.com/news-release/2022/08/03/2491463/0/en/Isracann-Biosciences-Announces-Closing-of-First-Tranche-of-0-05-Unit-Private-Placement.html?f=22&fvtc=4&fvtv=43461Isracann Biosciences Announces Closing of First Tranche of $0.05 Unit Private Placement2022-08-03T13:00:00Z<![CDATA[VANCOUVER, British Columbia, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement. The Company issued 4,679,600 units (the “Units”) at a price of $0.05 per Unit for aggregate gross proceeds of $233,980 (the “Offering”).]]>https://www.globenewswire.com/news-release/2022/05/19/2446936/0/en/Isracann-Biosciences-Subsidiary-Praesidio-Health-Submits-NPNs-to-Health-Canada.html?f=22&fvtc=4&fvtv=43461Isracann Biosciences Subsidiary Praesidio Health Submits NPNs to Health Canada2022-05-19T12:30:00Z<![CDATA[VANCOUVER, British Columbia, May 19, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted organization with a natural health medicine division in Canada and holdings in Israel, is pleased to announce that its wholly owned subsidiary Praesidio Health has completed the natural product number (NPN) submissions to Health Canada for its first formulations.]]>https://www.globenewswire.com/news-release/2022/04/15/2423273/0/en/Isracann-Biosciences-Renews-Leadership-to-Meet-Changing-Demands.html?f=22&fvtc=4&fvtv=43461Isracann Biosciences Renews Leadership to Meet Changing Demands 2022-04-15T12:30:00Z<![CDATA[VANCOUVER, British Columbia, April 15, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that further to its acquisition of Praesidio Health Inc. as a natural health medicine division, the Company has elected to expand its leadership team effective immediately.]]>https://www.globenewswire.com/news-release/2022/04/13/2421914/0/en/Isracann-Biosciences-Acquires-Natural-Health-Medicine-Developer-and-Appoints-Natural-Health-Products-Officers.html?f=22&fvtc=4&fvtv=43461Isracann Biosciences Acquires Natural Health Medicine Developer and Appoints Natural Health Products Officers2022-04-13T12:30:00Z<![CDATA[VANCOUVER, British Columbia, April 13, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that, further to the Company’s news releases dated February 23, 2022 and March 28, 2022, it has closed its acquisition of Praesidio Health Inc. (“Praesidio”). Pursuant to the definitive agreement dated March 24, 2022 with Praesidio and the shareholders of Praesidio (the “Praesidio Shareholders”), the Company acquired all of the issued and outstanding shares in the capital of Praesidio (the “Praesidio Shares”) for aggregate consideration of C$4,000,000 in common shares (the “Consideration Shares”) in the capital of the Company (the “Transaction”). Praesidio will operate as a wholly-owned subsidiary of the Company.]]>